These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25481796)

  • 1. Health state utilities associated with attributes of treatments for hepatitis C.
    Matza LS; Sapra SJ; Dillon JF; Kalsekar A; Davies EW; Devine MK; Jordan JB; Landrian AS; Feeny DH
    Eur J Health Econ; 2015 Dec; 16(9):1005-18. PubMed ID: 25481796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes.
    Matza LS; Boye KS; Stewart KD; Davies EW; Paczkowski R
    BMC Health Serv Res; 2017 Nov; 17(1):774. PubMed ID: 29178918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
    Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
    J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
    [No Abstract]   [Full Text] [Related]  

  • 4. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS).
    Matza LS; Phillips GA; Howell TA; Ciffone N; Ahmad Z
    J Med Econ; 2020 Sep; 23(9):978-984. PubMed ID: 32479143
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute and chronic impact of cardiovascular events on health state utilities.
    Matza LS; Stewart KD; Gandra SR; Delio PR; Fenster BE; Davies EW; Jordan JB; Lothgren M; Feeny DH
    BMC Health Serv Res; 2015 Apr; 15():173. PubMed ID: 25896804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes.
    Boye KS; Matza LS; Walter KN; Van Brunt K; Palsgrove AC; Tynan A
    Eur J Health Econ; 2011 Jun; 12(3):219-30. PubMed ID: 20224930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences.
    Matza LS; Deger KA; Vo P; Maniyar F; Goadsby PJ
    Qual Life Res; 2019 Sep; 28(9):2359-2372. PubMed ID: 30924071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health state utilities for skeletal-related events secondary to bone metastases.
    Matza LS; Chung K; Van Brunt K; Brazier JE; Braun A; Currie B; Palsgrove A; Davies E; Body JJ
    Eur J Health Econ; 2014 Jan; 15(1):7-18. PubMed ID: 23355121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilities for treatment-related adverse events in type 2 diabetes.
    Shingler S; Fordham B; Evans M; Schroeder M; Thompson G; Dewilde S; Lloyd AJ
    J Med Econ; 2015 Jan; 18(1):45-55. PubMed ID: 25266815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
    Hall F; de Freitas HM; Kerr C; Ito T; Nafees B; Lloyd AJ; Penton J; Hadi M; Lanar S; Pham TP
    Qual Life Res; 2019 May; 28(5):1191-1199. PubMed ID: 30767088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health State Utilities Associated with Glucose Monitoring Devices.
    Matza LS; Stewart KD; Davies EW; Hellmund R; Polonsky WH; Kerr D
    Value Health; 2017 Mar; 20(3):507-511. PubMed ID: 28292497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura.
    Szende A; Brazier J; Schaefer C; Deuson R; Isitt JJ; Vyas P
    Curr Med Res Opin; 2010 Aug; 26(8):1893-903. PubMed ID: 20553121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health state utilities for metastatic breast cancer in Taiwan.
    Chou TC; Chiang SC; Ko Y
    Breast; 2020 Jun; 51():57-64. PubMed ID: 32213442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of health state utilities associated with adult and pediatric acid sphingomyelinase deficiency (ASMD).
    Matza LS; Stewart KD; Fournier M; Rowen D; Lachmann R; Scarpa M; Mengel E; Obermeyer T; Ayik E; Laredo F; Pulikottil-Jacob R
    Eur J Health Econ; 2024 Nov; 25(8):1437-1448. PubMed ID: 38409492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elicitation of health state utilities associated with differing durations of morning stiffness in rheumatoid arthritis.
    Iqbal I; Dasgupta B; Taylor P; Heron L; Pilling C
    J Med Econ; 2012; 15(6):1192-200. PubMed ID: 22804691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health state utilities associated with post-surgical Staphylococcus aureus infections.
    Matza LS; Kim KJ; Yu H; Belden KA; Chen AF; Kurd M; Lee BY; Webb J
    Eur J Health Econ; 2019 Aug; 20(6):819-827. PubMed ID: 30887157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility score of epilepsy with partial seizure measured by TTO, VAS, and EQ-5D in the general Korean population.
    Kang HJ; Kang E; Jo MW; Park EJ; Yoon S; Lee EK
    Epilepsy Res; 2014 Jul; 108(5):963-71. PubMed ID: 24679945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of different scenarios for intermittent bladder catheterization on health state utilities: results from an internet-based time trade-off survey.
    Averbeck MA; Krassioukov A; Thiruchelvam N; Madersbacher H; Bøgelund M; Igawa Y
    J Med Econ; 2018 Oct; 21(10):945-952. PubMed ID: 29882712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales.
    Weernink MG; Groothuis-Oudshoorn CG; IJzerman MJ; van Til JA
    Value Health; 2016; 19(2):226-32. PubMed ID: 27021757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation.
    Matza LS; Boye KS; Feeny DH; Bowman L; Johnston JA; Stewart KD; McDaniel K; Jordan J
    Eur J Health Econ; 2016 Nov; 17(8):979-990. PubMed ID: 26611792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.